Fondazione Irccs Istituto Neurologico "Carlo Besta"

Milan 20133

16 studies enrolling now · 49 studies all time

What they study most

AB Variant Gangliosidosis GM2, AChR-Ab Seropositive Generalized Myasthenia Gravis, Advanced and Metastatic Cancer Patients With Tumors Harboring FGF/FGFR Tumors, Alzheimer Disease, Alzheimer's Disease, Alzheimer's Disease Dementia, Angelman Syndrome, Anti-myostatin, Atypical Parkinsonism, Behavioral Variant Frontotemporal Dementia (bvFTD), Brain Cancer, Brain Neoplasms

Studies at this site

• A Study to Evaluate the Safety and Efficacy of Oral Nizubaglustat (AZ-3102) in Late-infantile and Juvenile Forms of Niemann-Pick Type C Disease, GM1 Gangliosidosis or GM2 Gangliosidosis — Recruiting now
• PrProfile: A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ION717 — Recruiting now
• A Study to Evaluate the Safety and Efficacy of Oral Nizubaglustat (AZ-3102) in Late-infantile and Juvenile Forms of Niemann-Pick Type C Disease (NPC) — Recruiting now
• ADAPT Forward 1 - ISA1 - a Study to Evaluate Empasiprubart IV as add-on Therapy to Efgartigimod IV in Participants With AChR-Ab Seropositive Generalized Myasthenia Gravis With a Partial Clinical Response to Efgartigimod — Recruiting now
• ADAPT Forward - Master Protocol of a Platform Study to Evaluate the Safety and Efficacy of Multiple Regimens in Participants With Myasthenia Gravis — Recruiting now
• Pan Tumor Rollover Study — Recruiting now
• REVEAL: A Phase 3 Study of ION582 in Angelman Syndrome — Recruiting now
• Efficacy and Safety of a New Formulation of Oral Cladribine Compared With Placebo in Participants With Generalized Myasthenia Gravis (MyClad) — Recruiting now
• EF-41/KEYNOTE D58: Phase 3 Study of Optune Concomitant With Temozolomide Plus Pembrolizumab in Newly Diagnosed Glioblastoma — Recruiting now
• A Natural History Study in Participants With Congenital Myasthenic Syndromes (CMS) Due to Mutations in DOK7, MUSK, AGRN, or LRP4 — Recruiting now
• KHENERFIN Study: A Trial to Evaluate the Efficacy and Safety of Sonlicromanol in Primary Mitochondrial Diseases — Recruiting now
• Efficacy of KL1333 in Adult Patients With Primary Mitochondrial Disease — Recruiting now
• A Study to Learn More About the Effects and Long-Term Safety of Omaveloxolone (BIIB141) in Children and Teens With Friedreich's Ataxia — Recruiting now
• Evaluation of Efficacy and Safety of VX-993 for Pain Associated With Diabetic Peripheral Neuropathy — Recruiting now
• A Study to Evaluate How Apitegromab Works in Subjects Who Are Less Than 2 Years Old and Have Spinal Muscular Atrophy — Recruiting now
• HDClarity: a Multi-site Cerebrospinal Fluid Collection Initiative to Facilitate Therapeutic Development for Huntington's Disease — Recruiting now
• A Study to Evaluate the Safety and Effect of AVB-101, a Gene Therapy Product, in Subjects With a Genetic Sub-type of Frontotemporal Dementia (FTD-GRN) — Recruiting now
• Friedreich Ataxia Global Clinical Consortium UNIFIED Natural History Study — Recruiting now
• A Phase 1b Study to Investigate Safety and Tolerability of ARGX-119 in Adult Participants With DOK7-Congenital Myasthenic Syndromes (CMS) — Running, not enrolling
• A Study to Evaluate the Safety and Efficacy of Oral Nizubaglustat (AZ-3102) in Late-infantile and Juvenile Forms of GM1 Gangliosidosis or GM2 Gangliosidosis — Running, not enrolling
• Efficacy and Safety of Erenumab in Pediatric Participants With Episodic Migraine — Running, not enrolling
• A Trial of Amlenetug (Lu AF82422) in Participants With Multiple System Atrophy (MSA) — Running, not enrolling
• A Study to Assess Efficacy and Safety of Efgartigimod PH20 SC in Adults With Ocular Myasthenia Gravis — Running, not enrolling
• A Study to Learn About the Safety of Diranersen (BIIB080) Injections and Whether They Can Improve Symptoms of Participants With Mild Cognitive Impairment Due to Alzheimer's Disease (AD) or Mild AD Dementia Between 50 to 80 Years of Age — Running, not enrolling
• A Study to Learn About the Effect of Higher Doses of Nusinersen (BIIB058) Given as Injections to Participants With Spinal Muscular Atrophy (SMA) Who Were Previously Treated With Risdiplam (ASCEND) — Running, not enrolling
• AMX0035 and Progressive Supranuclear Palsy — Completed
• Erenumab - Comprehensive Assessment of Efficacy in (High-Frequency) Episodic Migraine — Completed
• Efficacy and Safety of Erenumab in Pediatric Subjects With Chronic Migraine — Completed
• Study of SRP-4045 (Casimersen) and SRP-4053 (Golodirsen) in Participants With Duchenne Muscular Dystrophy (DMD) — Completed
• Efficacy and Safety of Losmapimod in Treating Participants With Facioscapulohumeral Muscular Dystrophy (FSHD) (REACH) — Stopped early
• GM1 and GM2 Gangliosidosis PROspective Neurological Disease TrajectOry Study (PRONTO) — Completed
• A Study to Evaluate the Efficacy and Safety of Erenumab in Adults With Medication Overuse Headache — Completed
• A Study of TAS-120 in Patients With Advanced Solid Tumors — Completed
• A Study to Evaluate Safety and Tolerability of Aducanumab in Participants With Alzheimer's Disease Who Had Previously Participated in the Aducanumab Studies 221AD103, 221AD301, 221AD302 and 221AD205 — Stopped early
• NEURO-TTRansform: A Study to Evaluate the Efficacy and Safety of Eplontersen (Formerly Known as ION-682884, IONIS-TTR-LRx and AKCEA-TTR-LRx) in Participants With Hereditary Transthyretin-Mediated Amyloid Polyneuropathy — Completed
• Brain Tumor Intraoperative Ultrasound Database — Completed
• A Study to Assess if BIIB122 Tablets Are Safe and Can Slow Worsening of Early-Stage Parkinson's Disease in Participants With Specific LRRK2 Genetic Variants Between the Ages of 30 and 80 Using the Movement Disorder Society-Unified Parkinson's Disease Rating Scale — Stopped early
• A Study to Evaluate Efficacy, Safety, and Tolerability of EID of Natalizumab (BG00002) in Participants With RRMS Switching From Treatment With Natalizumab SID in Relation to Continued SID Treatment- Followed by Extension Study Comprising SC and IV Natalizumab Administration — Completed
• Evaluate Safety and Biological Activity of ATYR1940 in Participants With Early Onset Facioscapulohumeral Muscular Dystrophy — Completed
• Clinical Study to Evaluate the Efficacy and Safety of Givinostat in Ambulant Patients With Duchenne Muscular Dystrophy — Completed
• A Study to Evaluate the Efficacy and Safety of VX-150 in Treating Subjects With Pain Caused by Small Fiber Neuropathy — Completed
• Natural History Study for Pediatric Patients With Early Onset of Either GM1 Gangliosidosis, GM2 Gangliosidoses, or Gaucher Disease Type 2 — Completed
• 221AD302 Phase 3 Study of Aducanumab (BIIB037) in Early Alzheimer's Disease — Stopped early
• Safety and Efficacy of Eculizumab in Refractory Generalized Myasthenia Gravis (REGAIN Study) — Completed
• BMN 701 Phase 3 in rhGAA Exposed Subjects With Late Onset Pompe Disease (INSPIRE Study) — Stopped early
• Safety and Efficacy Study Evaluating TRx0237 in Subjects With Behavioral Variant Frontotemporal Dementia (bvFTD) — Completed
• Study Evaluating the Safety and Efficacy of Bapineuzumab in Alzheimer Disease Patients — Stopped early
• Study Evaluating The Efficacy And Safety Of Bapineuzumab In Alzheimer Disease Patients — Stopped early
• A Long-Term Safety And Tolerability Extension Study Of Bapineuzumab In Alzheimer Disease Patients — Stopped early